Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans.

YY-20394, a highly selective PI3Kδ inhibitor, is under NDA submission for treating follicular lymphoma in China. The absorption, metabolism, and excretion of YY-20394 were evaluated in healthy Chinese male subjects following a single oral dose of 80 mg [14C]YY-20394 (100 µCi).Within 264 h post-dose, 92.1% of the administered dose was recovered, with 58.1% from urine and 34.0% from faeces. YY-20394 was rapidly absorbed in humans, and the peak plasma concentrations occurred at 1.0 h. The absorbed drug fraction was at least 58.1% according to urine recovery.In addition to the parent drug, nine metabolites were identified in plasma, urine, and faeces. Unchanged YY-20394 was the predominant drug-related component in plasma (accounting for 68.4% of the total radioactivity), urine (accounting for 90.0% of the urinary radioactivity) and faeces (accounting for 41.7% of the faecal radioactivity). In humans, the major metabolic sites were the morphine ring and side chains of piperidine rings. The major metabolic pathways involved N-dealkylation, O-dealkylation, glucuronidation and acetylation.Overall, renal elimination played a significant role in the disposition of YY-20394, and the morphine ring and the side chain of the piperidine ring was the predominant metabolic sites.

The effects of Lu3+, Gd3+ and Ga3+ substitution on the photoluminescence of Y2.95-x-yLuxGdyAlzGa5-zO12:0.05Ce3+ phosphors for high-power white AC-LEDs.

Various yellowish-green persistent phosphors of Y2.95-x-yLuxGdyAl5-zGazO12:0.05Ce3+ (x = 0-1, y = 0-1, z = 1-4) were successfully synthesized by the one-step high-temperature solid-state reaction method in air. The effects of simultaneous doping of Lu3+, Gd3+ and Ga3+ on the luminescence properties of the phosphors were investigated in detail for the first time. Herein, the microstructure, morphology, afterglow performance, luminescence properties, thermoluminescence, thermal quenching and flicker index of the efficient blue-light-activated Y2.95-x-yLuxGdyAl5-zGazO12:0.05Ce3+ phosphors were tested. The τ90 and τ80 values of Y1.45LuGd0.5Al2.5Ga2.5O12:0.05Ce3+ are 10.8 ms and 33.2 ms, respectively. These parameters are important in terms of effectiveness in reducing flicker in alternating current (AC) LEDs. Compared with the conventional Y3Al2Ga3O12:Ce3+ phosphor, the Y1.45LuGd0.5Al2.5Ga2.5O12:0.05Ce3+ phosphor has a better luminescence performance, stronger afterglow performance, and lower flicker index. The quantum yield of the Y1.45LuGd0.5Al2.5Ga2.5O12:0.05Ce3+ phosphor was 86.42% and the luminous efficiency of the LED devices prepared with it reached 92.12 lm W-1 when operated at 100 mA. Integrating sphere and spectroradiometer tests as well as CIE chromaticity diagrams indicate that the AC-WLEDs assembled by mixing the Y1.45LuGd0.5Al2.5Ga2.5O12:0.05Ce3+ phosphor and a commercial red phosphor in an appropriate ratio could obtain ideal white light with a high color-rendering index (87.9) and the flickering index was successfully reduced from 100% to 61.4%.

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.

PURPOSE: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. PATIENTS AND METHODS: Histologically confirmed relapsed and/or refractory patients with FL with disease progression after receiving second-line or greater systemic therapy were enrolled. Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred. The primary outcome for the study was the objective response rate (ORR), with secondary outcomes including the duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate, and drug safety profile. RESULTS: Of 114 screened relapsed and/or refractory patients with FL, 84 were enrolled in the full analysis set (FAS). The ORR of the 84 FAS patients was 79.8% [95% confidence interval (CI), 69.6-87.8, 67 patients], with 13 patients (15.5%) achieving a complete response and 54 patients (64.3%) with a partial response. The median DOR was 12.3 months (95% CI, 9.3-15.9). The median PFS was 13.4 months (95% CI, 11.1-16.7). The 12-month OS rate was 91.4% (95% CI, 82.7-95.8) and a median OS not reached by 42 months. The most frequent (>3%) treatment-related adverse events Grade ≥3 were infectious pneumonia (19.0%), neutropenia (15.5%), decreased lymphocyte count (4.8%), decreased leukocyte count (4.8%), increased lipase (3.6%), decreased platelet count (3.6%), hypertriglyceridemia (3.6%), and interstitial lung disease (3.6%). CONCLUSIONS: Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory patients with FL who had received at least two prior systemic therapies.

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.

YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patients received 20-200 mg of YY-20394 daily. The primary outcome measures were tolerability and dose-limiting toxicity (DLT). The secondary outcomes were pharmacokinetic parameters, progression-free survival (PFS) and the objective response rate (ORR). Since no patients experienced DLT, the maximum tolerated dose (MTD) was not reached. The majority (≥ 5%) of drug-related adverse events were ≥ grade III, being neutropenia (44.0%), pneumonia (16.0%), hyperuricemia (12.0%), lymphocythemia (8.0%), leukopenia (8.0%) and pneumonitis (8.0%). The overall ORR was 64.0% (95% confidence interval (CI): 45.2, 82.8%) including 5 patients with complete remission (CR), 11 with partial remission (PR), 2 with stable disease (SD) and 7 with progressive disease (PD), while the disease control rate (DCR) was 72.0% (95% CI: 54.4, 89.6%). The ORR of 10 patients with follicular lymphoma was 90%. The median PFS time was 255 days. One PR patient with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received 40 mg q.d. had a durable response of around 36 months. The median PFS time of 10 patients with follicular lymphoma was 300 days. A recommended phase 2 dose of 80 mg q.d. was established. Considering that YY-20394 was well-tolerated with promising preliminary efficacy, further development is warranted.Trial registration clinicaltrials.gov, NCT03757000, retrospectively registered, November 28, 2018, https://clinicaltrials.gov/ct2/show/NCT03757000?term=NCT03757000&draw=2&rank=1 .

4-Azido-2-pyrimidinone Nucleosides and Related Chemistry.

As a part of azide prodrug approach, we synthesized a 4-azido analog of ara-C (4) as a prodrug for ara-C. The compound 4 was obtained from 1-(beta-D-arabinofuranosyl)uracil (1) in three steps. At pH 7.0 and 11.0, a loss of UV absorption of the compound 4 was observed resulting from a transformation that was proved by identifying the transformed product 5 by 1-D, and 2-D NMR as well as tandem mass spectral studies. In NMR studies, changes in the chemical shifts were observed at positions 5, 6, 1', and 2' between the compounds 4 and 5. A molecular peak at m/z 270.1 (MH(+)) was observed in the mass spectra of compounds 4 and the transformed product 5. A fragment at 180.2 was identified to be the compound 6, containing the 6,2'-anhydro linkage of compound 5. The X-ray analysis indicated that compound 4 exists as 1-(beta-D-arabinofuranosyl)tetrazolo[4,5-c]pyrimidin-2-one, with the azide moiety cyclized. To understand if the chemical instability of the nucleoside 4 was due to the arabino configuration of 2'-OH or due to the azido moiety, we also studied 1-(2,3-dideoxy-2-fluoro-beta-D-arabinofuranosyl)tetrazolo[4,5-c]pyrimidin-2-one (11) and 4-azido-1-methyl-2-pyrimidinone (15). At pH 2.0 and 7.0, similar UV profiles were observed for compounds 11 and 15. However, at pH 11.0, lambda(max) shifted slowly to lower wavelength for both compounds 11 and 15. In a separate kinetic study, they were stable at pH 7.4 for up to 2.45 h. From the NMR and high-resolution mass spectral studies, it was concluded that in the presence of ammonium hydroxide, an addition of amine occurred at 6-position of compound 11. Thus, the stability profiles of compounds 4, 11, and 15 were different. The instability and the formation of 2',6-anhydro bond in compound 4 in nonacidic media was due to the presence of 2'-OH in the arabino configuration and probably not due to the azide group.